Key facts
- Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for approximately $10 billion.
- The acquisition includes Crinetics' marketed drug PALSONIFY and its Phase 3 candidate atumelnant.
- PALSONIFY is an oral therapy for adults with acromegaly.
- Atumelnant is an ACTH receptor antagonist in Phase 3 development for congenital adrenal hyperplasia.
- The transaction was unanimously approved by both companies' boards of directors.
- The deal is expected to close in the third quarter of 2026.
Vertex Pharmaceuticals has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for approximately $10 billion in cash. The deal, which was unanimously approved by both companies' boards, is expected to close in the third quarter of 2026.
Crinetics brings to Vertex a portfolio of endocrinology assets, including its recently launched drug PALSONIFY (paltusotine) for acromegaly and its Phase 3 candidate atumelnant, an ACTH receptor antagonist for congenital adrenal hyperplasia (CAH). Vertex anticipates that the acquisition will expand its reach beyond its current focus areas into rare endocrine diseases.
